Artiva Biotherapeutics (ARTV) Financials

Artiva Biotherapeutics’ Q2 2026 statements show a substantially stronger liquidity position, but the company remains a pre-revenue biotechnology business with persistent operating losses and significant cash burn.

• Liquidity improved sharply. Cash and equivalents rose to $301.5 million at June 30, 2026, from $21.0 million at March 31. Including $47.9 million of short-term investments, Artiva held approximately $349.4 million in liquid assets.
• The balance sheet is lightly leveraged. Total liabilities were $21.1 million compared with $347.5 million of equity. Current assets of $352.3 million significantly exceeded current liabilities of $14.6 million, indicating substantial short-term financial flexibility.
• Recent financing materially extended the company’s funding position. Artiva reported $283.3 million of net cash from financing activities in Q2, primarily from issuing common equity. This drove the quarterly net increase in cash to $280.5 million.
• Operating cash burn moderated modestly sequentially. Net cash used in operating activities declined to $20.4 million in Q2 from $21.0 million in Q1 2026, although the burn rate remains significant.
• Interest and investment income provides a modest offset to operating losses. Q2 interest and investment income was $1.9 million, up from $912,000 in Q1, supported by the company’s sizable cash and investment balances.
• Estimated liquidity runway appears extended, but depends on continued spending discipline. Q2 cash and short-term investments equaled roughly 17 quarters of operating cash use based on the quarter’s $20.4 million burn. This is only a rough estimate because investment maturities, clinical spending and future financing activity can vary substantially.
• Investment activity has been a major source of cash-flow volatility. Artiva generated $18.0 million from sales or maturities of investments in Q2, following $22.0 million in Q1. These transactions improve reported investing cash flow but do not represent recurring operating revenue.
• Artiva has not generated meaningful revenue in the recent periods provided. Revenue was $0 in Q2 2026 and Q1 2026, consistent with the reported Q2-Q4 2025 periods. The company reported $251,000 of revenue in Q1 2024 and $26.7 million in Q3 2023, highlighting the volatility and lack of a current commercial revenue base.
• Net losses remain persistent and have generally widened from historical levels. Q2 2026 net loss was $25.0 million, compared with $23.5 million in Q1, $20.8 million in Q4 2025 and $17.5 million in Q3 2024. The company has reported losses in nearly all of the recent quarters provided.
• Research and development spending continues to rise. Q2 R&D expense increased to $21.9 million from $19.3 million in Q1 and $17.0 million in Q4 2025. Total operating expenses reached $26.9 million, reinforcing that clinical development remains the primary use of capital.
• The equity financing significantly increased dilution risk. Weighted average basic shares outstanding rose to 39.4 million in Q2 from 24.7 million in Q1. Common stock on the balance sheet increased by approximately $284.7 million sequentially, broadly consistent with the reported equity issuance.

Overall, the Q2 financing substantially strengthened Artiva’s balance sheet and reduced near-term financing pressure. However, the company’s investment case remains dependent on clinical and commercial progress because it currently has no meaningful recurring revenue, continues to consume more than $20 million in operating cash per quarter, and has funded its improved liquidity partly through substantial equity issuance.